Subgroups of primary Sjögren's syndrome. Sjögren's syndrome in male and paediatric Greek patients

Alexandros A Drosos, Eleni K Tsiakou, Niki Tsifetaki, Eudokia N Politi, Antigoni Siamopoulou-Mavridou

Abstract

Objectives—To describe the clinical and serological findings in male and paediatric Sjögren's syndrome (SS) patients.

Patients and Methods—Using the European criteria for the diagnosis of SS 12 male and 13 paediatric patients were identified and compared with those of 30 consecutive unselected adult female SS patients.

Results—The mean (SD) age of paediatric patients was 9.4 (2.2) years, ranging from 6 to 14 years. Recurrent parotid gland enlargement was the initial clinical manifestation in the majority of the children with a statistical significance compared with male ($p < 0.01$) and with female patients ($p < 0.0001$). Sicca manifestations were the most common clinical symptoms in male and female patients at disease onset. The systemic manifestations were similar among the three groups except that men showed lower frequency of arthritis ($p < 0.05$) and Raynaud's phenomenon ($p < 0.05$) compared with women. No differences were found among the immunological profile of children and female patients, while male patients had a lower frequency of antinuclear antibodies ($p < 0.025$) and antibodies to Ro(SSA) nuclear antigens ($p < 0.025$) compared with women.

Conclusion—Primary SS is rare in children and men in Greece. Recurrent parotid gland enlargement is the most common clinical finding at disease onset in children. Male patients seem to have less systemic manifestations and lower frequency of autoantibodies.

(*Ann Rheum Dis* 1997;56:333-335)

Primary Sjögren's syndrome (SS) is a chronic autoimmune disorder affecting the lacrimal and salivary glands, as well as other exocrine glands leading to functional impairment and mucosal dryness. It is often associated with systemic extraglandular manifestations, and laboratory tests show B cell polyclonal hyperactivity. It affects predominantly women at middle age.^{1,2} Although the first case reported by Dr Mikulicz was a 42 year old man,³ there are only few reports describing the clinical picture of SS in males.⁴⁻⁶ In children only case reports of SS have been reported.⁷⁻¹⁰

In this study we present 12 male and 13 paediatric patients and compare their clinical and serological findings with those of 30 adult female SS patients.

Patients and methods

In the past 15 years we have diagnosed 16 children and 13 men with primary SS. We have prospectively reevaluated the exocrine glands and related symptomatology of all these patients, and compared them with those of 30 sequential, unselected adult female SS patients. None of our female paediatric patients had menses at the onset of the disease while 22 of 30 adult female SS patients had regular menstrual cycles during the study period.

All patients had a complete physical examination and routine laboratory tests. After written consent was obtained, all patients underwent a minor salivary gland biopsy under local anaesthesia. All patients' serum samples were tested for the presence of rheumatoid factor (RF) (latex test), antinuclear antibodies (ANA) (indirect immunofluorescence using Hep-2 cell lines), antibodies to Ro(SSA), La(SSB), Sm and U₁RNP nuclear antigens (counter immunoelectrophoresis), and C₃ and C₄ complement values.

For the diagnosis of primary SS we used the preliminary European criteria.¹¹

For statistical analysis of the results, the Student *t* test and χ^2 test with Yates's correction were used.

Results

We have identified 13 paediatric (11 girls, 2 boys) and 12 male patients. Paediatric and male SS patients were identified from our SS cohort of 292 primary SS cases and represent about 4% of our SS population, while the total of juvenile polyarthritis patients seen in our paediatric clinic was 298. Three paediatric patients and one man were excluded from the study because: two children had an associated disease, juvenile chronic polyarthritis and the other one did not meet the European criteria for SS. The male patient, who also was excluded from the study, had sarcoidosis.

Table 1 shows the mean age and disease duration. Recurrent parotid gland enlargement (RPGE) was the initial clinical manifestation in the majority of the children (77%) with a statistical significance compared with other groups. Sicca manifestations were the most

Departments of Internal Medicine

A A Drosos
E K Tsiakou
N Tsifetaki
E N Politi

and Paediatrics

A Siamopoulou-Mavridou

Medical School,
University of Ioannina,
Ioannina, Greece

Correspondence to:
Dr A A Drosos, Department
of Internal Medicine,
Medical School, University of
Ioannina, 45110 Ioannina,
Greece.

Accepted for publication
14 February 1997

Table 1 Comparison of clinical and laboratory findings between subgroups with primary Sjögren's syndrome patients

Characteristics	Children (n=13)	Men (n=12)	Female (n=30)	p Value
Age at onset (y) (mean(SD))	9.4 (2.8)	45.3 (5.5)	46.4 (6.1)	
Disease duration (y) (mean(SD))	6.5 (3.2)	11.2 (5.0)	10.5 (5.4)	
First manifestations				
Sicca syndrome	3 (23%)	9 (75%)*	23 (77%)†	p < 0.05*, p < 0.005†
RPGE	10 (77%)	2 (17%)*	4 (13%)†	p < 0.01*, p < 0.0001†
EGM	—	1 (8%)	3 (10%)	NS
Extraglandular manifestations during disease				
Constitutional symptoms	3 (23%)	4 (33%)	7 (23%)	NS
Musculoskeletal	3 (23%)	1 (8%)	14 (47%)	p < 0.05
Raynaud's phenomenon	4 (31%)	1 (8%)	13 (43%)	p < 0.05
Lymphadenopathy	3 (23%)	4 (33%)	5 (17%)	NS
Hepatomegaly	1 (8%)	2 (17%)	4 (13%)	NS
Skin involvement	—	—	1 (3%)	NS
Pulmonary involvement	—	—	1 (3%)	NS
Autoantibodies				
RF	6 (46%)	8 (67%)	16 (53%)	NS
ANA	9 (69%)	4 (33%)	23 (77%)	p < 0.025
Ro (SSA)	7 (54%)	2 (17%)	19 (63%)	p < 0.025
La (SSB)	4 (31%)	1 (8%)	11 (37%)	NS

RPGE = recurrent parotid gland enlargement; EGM = extraglandular manifestations. * = statistically significant between children and men. † = statistically significant between children and women.

common clinical symptoms in male and female patients at disease onset. The extraglandular manifestations were similar among the three groups except that male patients showed lower frequency of arthritis and Raynaud's phenomenon compared with female patients (table 1).

No differences were found among the immunological profile of children and female adult patients. The immunological profile of male patients showed a lower frequency of ANA ($p < 0.025$) and antibodies to Ro(SSA) nuclear antigens ($p < 0.025$) compared with female patients (table 1).

Discussion

The main purpose of this study was to clarify the clinical and serological findings in paediatric and male SS patients, using at present uniformly accepted European criteria.¹¹ In most of the cases reported in the medical literature previously, there is no distinction between primary and secondary SS.⁷⁻¹⁰

In our study, which is a controlled comparative study, we have excluded three children: two of them had another underlying disease, and the third did not have positive minor salivary gland biopsy. One man also was excluded because the minor salivary gland biopsy showed granuloma, compatible with sarcoidosis. We found that children showed the same glandular and systemic manifestations during the course of the disease compared with adult female patients. However, RPGE was the most common initial clinical manifestation in the majority of the children (77%) compared with male and adult female patients. These findings are in agreement with most of the investigators who reported that RPGE is the major clinical finding in children.⁷⁻¹⁰

On the other hand in a study of 36 men and 69 women with primary SS, Molina *et al* found that men run the same risk as women of developing systemic manifestations, but few had increase concentrations of RF and anti-Ro(SSA) antibodies.⁵ In this study we found that SS in male patients had a tendency to be less severe with lower frequency of arthritis and Raynaud's phenomenon and with lower

frequency of autoantibodies in their serum. These findings are partially in agreement with those reported by Molina, who found more extraglandular manifestations and less autoantibodies in their male patients. However, our results are in agreement also with those reported by others who found that extraglandular manifestations in SS are associated with the presence of many autoantibodies.¹

Our results are in contrast with those reported by Anaya *et al* who found that male patients have more systemic manifestations, with more autoantibodies in their serum.⁶ These differences could be explained by the different genetic background in the study population. Primary SS patients have been found to be associated with the HLA-class II antigens, especially HLA-DRW₅₂ or HLA-DR₃, or both, whereas SS accompanying rheumatoid arthritis is linked with the HLA-DR₄.¹² In 1988 we reported that primary SS patients were associated with the HLA-DR₃ alloantigen. The prevalence of HLA-DR₃ was found in only 30% of our patients with no statistical significance compared with normal controls.¹³ Studying the natural course of 120 SS patients we have identified eight cases with lymphomas. Six were called low grade (immunocytomas) and two intermediate grade non-Hodgkin's lymphomas. These lymphomas tend to evolve very slowly and may regress spontaneously¹⁴ and differ from those reported previously by Talal and Bunim who showed that high grade lymphomas were more common in SS patients.¹⁵ These genetic variabilities may contribute to the clinical differences observed in our SS male patients.

In conclusion, it seems that primary SS in paediatric and male patients is rare. Recurrent parotid gland enlargement is the most common clinical finding at disease onset in children. Male patients seem to have less systemic manifestations and lower frequency of autoantibodies.

We are indebted to professor H M Moutsopoulos for critically reading our manuscript and we also thank Mrs E Horti for her excellent secretarial assistance.

- 1 Talal N, Moutsopoulos HM, Kassan SS, eds. *Sjögren's syndrome: clinical and immunological aspects*. Berlin: Springer Verlag, 1987.
- 2 Moutsopoulos HM. Sjögren's syndrome: autoimmune epitheliitis. *Clin Immunol Immunopathol* 1994;72:162-5.
- 3 Mikulicz J. Discussion at Verein für wissenschaftliche Heilkunde zu Königsberg. *Berl Klin Wochenschr* 1888; 25:759.
- 4 Hara Y, Mikaska N, Nishido T, Ukuda M. Clinical study on nine male cases with Sjögren's syndrome. *Ryumachi* 1979; 19:410-4.
- 5 Molina R, Provost TT, Arnett FC, Bias WB, Hochberg MC, Wilson RW, Alexander EL. Primary Sjögren's syndrome in men. Clinical, serological and immunogenetic features. *Am J Med* 1986;80:23-31.
- 6 Anaya JM, Lin GT, D'souza E, Ogawa N, Luan X, Talal N. Primary Sjögren's syndrome in men. *Ann Rheum Dis* 1995;54:748-51.
- 7 Chudwin DS, Daniels TE, Wara DW, Ammann AJ, Barrett DJ, Whitcher JP, *et al.* Spectrum of Sjögren's syndrome in children. *J Pediatr* 1981; 98:213-7.
- 8 Mizuno Y, Hara T, Hatae K, Hirano T, Ueda K, Nakamura N, *et al.* Recurrent parotid gland enlargement as an initial manifestation of Sjögren's syndrome in children. *Eur J Pediatr* 1989;148:414-6.
- 9 Siamopoulou-Mavridou A, Drosos AA, Andonopoulos AP. Sjögren's syndrome in childhood: report of two cases. *Eur J Pediatr* 1989;148:523-4.
- 10 Anaya JM, Ogawa N, Talal N. Sjögren's syndrome in childhood. *J Rheumatol* 1995; 22:1152-8.
- 11 Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, *et al.* Preliminary criteria for the classification of Sjögren's syndrome. *Arthritis Rheum* 1993;36:340-7.
- 12 Moutsopoulos HM, Mann DL, Johnson AH, Chused TM. Genetic differences between primary and secondary sicca syndrome. *N Engl J Med* 1979;301:761-3.
- 13 Papasteriades CA, Skopouli FN, Drosos AA, Andonopoulos AP, Moutsopoulos HM. HLA-alloantigen associations in Greek patients with Sjögren's syndrome. *J Autoimmun* 1988;1:85-90.
- 14 Pavlidis NA, Drosos AA, Papadimitriou C, Talal N, Moutsopoulos HM. Lymphoma in Sjögren's syndrome. *Med Pediatr Oncol* 1992;20:279-83.
- 15 Talal N, Bunim JJ. The development of malignant lymphoma in the course of Sjögren's syndrome. *Am J Med* 1964;36:529-40.